Abstract
Lubefaro et al 1 Lobefaro R Mariani L Peverelli G et al. Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: a monocentric, retrospective comparison. Clin Breast Cancer. 2022; (S1526-8209(22)00286-5Epub ahead of print)https://doi.org/10.1016/j.clbc.2022.12.008 Abstract Full Text Full Text PDF Scopus (0) Google Scholar evaluated the efficacy of first-line carboplatin-paclitaxel (CP) or carboplatin-gemcitabine (CG) combinations in 88 advanced triple-negative breast cancer (TNBC) patients. They concluded that CG and CP are effective and well tolerated first-line platinum doublets in advanced TNBC patients and CG could be more effective than CP in patients previous exposed to taxanes despite worse toxicity profile. However, the time interval between neoadjuvant treatment of a taxane regimen and development of metastatic disease was not described. Current literature does not define the exact interval by which taxane resistance is resolved. In the current study, a time interval pattern till time of metastases for patients exposed to previous taxanes (within 1 year, between 1 and 2 years, or more than 2 years) might predict that some patients previously exposed to taxanes might get more benefit from the taxane rechallenge.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
